BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 33511049)

  • 1. Optimal Management of Cirrhotic Ascites: A Review for Internal Medicine Physicians.
    Gallo A; Dedionigi C; Civitelli C; Panzeri A; Corradi C; Squizzato A
    J Transl Int Med; 2020 Dec; 8(4):220-236. PubMed ID: 33511049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cirrhosis and Portal Hypertension: How Do We Deal with Ascites and Its Consequences.
    Tonon M; Piano S
    Med Clin North Am; 2023 May; 107(3):505-516. PubMed ID: 37001950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis and therapy of ascites in liver cirrhosis.
    Biecker E
    World J Gastroenterol; 2011 Mar; 17(10):1237-48. PubMed ID: 21455322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of ascites in patients with end-stage liver disease.
    Saadeh S; Davis GL
    Rev Gastroenterol Disord; 2004; 4(4):175-85. PubMed ID: 15580152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.
    Testino G; Ferro C; Sumberaz A; Messa P; Morelli N; Guadagni B; Ardizzone G; Valente U
    Hepatogastroenterology; 2003; 50(54):1753-5. PubMed ID: 14696397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of ascites and hepatorenal syndrome.
    Piano S; Tonon M; Angeli P
    Hepatol Int; 2018 Feb; 12(Suppl 1):122-134. PubMed ID: 28836115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ePTFE-TIPS vs repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis.
    Bucsics T; Hoffman S; Grünberger J; Schoder M; Matzek W; Stadlmann A; Mandorfer M; Schwabl P; Ferlitsch A; Peck-Radosavljevic M; Trauner M; Karner J; Karnel F; Reiberger T
    Liver Int; 2018 Jun; 38(6):1036-1044. PubMed ID: 29091351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment for cirrhotic ascites.
    Kawaratani H; Fukui H; Yoshiji H
    Hepatol Res; 2017 Feb; 47(2):166-177. PubMed ID: 27363974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of refractory ascites and hepatorenal syndrome.
    Sussman AN; Boyer TD
    Curr Gastroenterol Rep; 2011 Feb; 13(1):17-25. PubMed ID: 21080246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ascites in cirrhosis: a review of management and complications.
    Kuiper JJ; van Buuren HR; de Man RA
    Neth J Med; 2007 Sep; 65(8):283-8. PubMed ID: 17890787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cirrhotic ascites review: Pathophysiology, diagnosis and management.
    Moore CM; Van Thiel DH
    World J Hepatol; 2013 May; 5(5):251-63. PubMed ID: 23717736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Ascites.
    Choudhury J; Sanyal AJ
    Curr Treat Options Gastroenterol; 2003 Dec; 6(6):481-491. PubMed ID: 14585237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human Albumin Infusion for the Management of Liver Cirrhosis and Its Complications: An Overview of Major Findings from Meta-analyses.
    Zheng X; Bai Z; Wang T; Romeiro FG; Mancuso A; Philips CA; Wong YJ; Nery FG; Qi X
    Adv Ther; 2023 Apr; 40(4):1494-1529. PubMed ID: 36697778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translating Our Current Understanding of Ascites Management into New Therapies for Patients with Cirrhosis and Fluid Retention.
    Pose E; Cardenas A
    Dig Dis; 2017; 35(4):402-410. PubMed ID: 28468013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transjugular intrahepatic portosystemic shunt versus paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: a prospective randomized trial.
    Narahara Y; Kanazawa H; Fukuda T; Matsushita Y; Harimoto H; Kidokoro H; Katakura T; Atsukawa M; Taki Y; Kimura Y; Nakatsuka K; Sakamoto C
    J Gastroenterol; 2011 Jan; 46(1):78-85. PubMed ID: 20632194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The transjugular intrahepatic portosystemic shunt for the management of cirrhotic refractory ascites.
    Garcia-Tsao G
    Nat Clin Pract Gastroenterol Hepatol; 2006 Jul; 3(7):380-9. PubMed ID: 16819501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy and safety of large volume paracentesis in cirrhotic patients with spontaneous bacterial peritonitis: a randomized prospective study].
    Choi CH; Han KH; Kim DY; Cho JH; Cheong JY; Song KH; Chon CY; Moon YM
    Taehan Kan Hakhoe Chi; 2002 Mar; 8(1):52-60. PubMed ID: 12499817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review article: Management of ascites and associated complications in patients with cirrhosis.
    Kuiper JJ; de Man RA; van Buuren HR
    Aliment Pharmacol Ther; 2007 Dec; 26 Suppl 2():183-93. PubMed ID: 18081661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morbidity and mortality after transjugular intrahepatic portosystemic shunt placement in patients with cirrhosis.
    Dissegna D; Sponza M; Falleti E; Fabris C; Vit A; Angeli P; Piano S; Cussigh A; Cmet S; Toniutto P
    Eur J Gastroenterol Hepatol; 2019 May; 31(5):626-632. PubMed ID: 30550458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Automated low-flow ascites pump for the treatment of cirrhotic patients with refractory ascites.
    Stirnimann G; Banz V; Storni F; De Gottardi A
    Therap Adv Gastroenterol; 2017 Feb; 10(2):283-292. PubMed ID: 28203285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.